Study of CEB-01 for resectable pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental drug called CEB-01 in people with pancreatic cancer that can be surgically removed. It aims to see if adding this drug to surgery improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have pancreatic cancer that has not spread beyond the pancreas and can be removed with surgery.
- You have not had cancer worsen during prior chemotherapy.
- You are healthy enough for surgery and have acceptable blood counts, kidney, and liver function.
- You are willing to use effective birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests EF-009, a study medicine, in adults with pancreatic cancer that doctors consider “borderline resectable” or “unresectable.” The goal is to see how safe it is and how well it works for this situation.
This trial uses a special technique called single-cell sequencing to study pancreatic cancer cells from patients whose tumors can be surgically removed or are on the edge of being removable. Participation may help researchers understand the disease better and could guide future treatments.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This trial tests whether a special dye (SGM-101) can help surgeons see remaining cancer cells during surgery for pancreatic cancer that has been treated before surgery. It may lead to more complete removal of the tumor.
This trial tests a new drug called CEND-1 combined with standard chemotherapy for people with advanced pancreatic cancer that has not been treated before. It aims to see if the combination works better than chemo alone.
Hear when a new Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.